136 related articles for article (PubMed ID: 8169852)
1. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
Zernig G; Butelman ER; Lewis JW; Walker EA; Woods JH
J Pharmacol Exp Ther; 1994 Apr; 269(1):57-65. PubMed ID: 8169852
[TBL] [Abstract][Full Text] [Related]
2. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
3. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice.
Burke TF; Woods JH; Lewis JW; Medzihradsky F
J Pharmacol Exp Ther; 1994 Nov; 271(2):715-21. PubMed ID: 7965787
[TBL] [Abstract][Full Text] [Related]
4. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
Barrett AC; Smith ES; Picker MJ
J Pharmacol Exp Ther; 2003 Jun; 305(3):1061-70. PubMed ID: 12649297
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
Zernig G; Burke T; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
[TBL] [Abstract][Full Text] [Related]
6. Methoclocinnamox: agonist and antagonist effects of a novel long-lasting opioid in rhesus monkeys.
Butelman ER; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Nov; 279(2):934-8. PubMed ID: 8930202
[TBL] [Abstract][Full Text] [Related]
7. Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: comparison with effects on opioid agonist-mediated antinociception.
Zernig G; Lewis JW; Woods JH
Psychopharmacology (Berl); 1997 Feb; 129(3):233-42. PubMed ID: 9084061
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the antinociceptive effect of acute morphine in female and male Sprague-Dawley rats using the long-lasting mu-antagonist methocinnamox.
Peckham EM; Barkley LM; Divin MF; Cicero TJ; Traynor JR
Brain Res; 2005 Oct; 1058(1-2):137-47. PubMed ID: 16139823
[TBL] [Abstract][Full Text] [Related]
9. Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys.
Pitts RC; Allen RM; Walker EA; Dykstra LA
J Pharmacol Exp Ther; 1998 Jun; 285(3):1197-206. PubMed ID: 9618423
[TBL] [Abstract][Full Text] [Related]
10. Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
Comer SD; Burke TF; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1992 Sep; 262(3):1051-6. PubMed ID: 1326622
[TBL] [Abstract][Full Text] [Related]
11. 3-Alkyl ethers of clocinnamox: delayed long-term mu-antagonists with variable mu efficacy.
Husbands SM; Sadd J; Broadbear JH; Woods JH; Martin J; Traynor JR; Aceto MD; Bowman ER; Harris LS; Lewis JW
J Med Chem; 1998 Aug; 41(18):3493-8. PubMed ID: 9719602
[TBL] [Abstract][Full Text] [Related]
12. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
Kögel B; Christoph T; Strassburger W; Friderichs E
Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
[TBL] [Abstract][Full Text] [Related]
13. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
[TBL] [Abstract][Full Text] [Related]
14. Antinociceptive and respiratory effects of nalbuphine in rhesus monkeys.
Gerak LR; Butelman ER; Woods JH; France CP
J Pharmacol Exp Ther; 1994 Nov; 271(2):993-9. PubMed ID: 7965822
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure.
Walker EA; Zernig G; Woods JH
J Pharmacol Exp Ther; 1995 Jun; 273(3):1345-52. PubMed ID: 7791107
[TBL] [Abstract][Full Text] [Related]
16. Clocinnamox dose-dependently antagonizes morphine-analgesia and [3H]DAMGO binding in rats.
Paronis CA; Woods JH
Eur J Pharmacol; 1997 Oct; 337(1):27-34. PubMed ID: 9389377
[TBL] [Abstract][Full Text] [Related]
17. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
[TBL] [Abstract][Full Text] [Related]
18. The effect of the irreversible mu-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA.
Chan K; Brodsky M; Davis T; Franklin S; Inturrisi CE; Yoburn BC
Eur J Pharmacol; 1995 Dec; 287(2):135-43. PubMed ID: 8749027
[TBL] [Abstract][Full Text] [Related]
19. Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine.
Negus SS; Burke TF; Medzihradsky F; Woods JH
J Pharmacol Exp Ther; 1993 Nov; 267(2):896-903. PubMed ID: 8246165
[TBL] [Abstract][Full Text] [Related]
20. Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism.
Jiang Q; Seyed-Mozaffari A; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1995 May; 273(2):680-8. PubMed ID: 7752070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]